CUTOMYA Trademark

Trademark Overview


On Thursday, January 12, 2017, a trademark application was filed for CUTOMYA with the United States Patent and Trademark Office. The USPTO has given the CUTOMYA trademark a serial number of 87299360. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 21, 2022. This trademark is owned by Allergan Sales, LLC. The CUTOMYA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable...
cutomya

General Information


Serial Number87299360
Word MarkCUTOMYA
Filing DateThursday, January 12, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 21, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 2, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 19, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Tuesday, February 22, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 21, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 21, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 20, 2021EXTENSION 5 GRANTED
Monday, July 12, 2021EXTENSION 5 FILED
Monday, July 19, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 12, 2021TEAS EXTENSION RECEIVED
Saturday, January 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 7, 2021EXTENSION 4 GRANTED
Thursday, January 7, 2021EXTENSION 4 FILED
Thursday, January 7, 2021TEAS EXTENSION RECEIVED
Tuesday, June 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 26, 2020EXTENSION 3 GRANTED
Friday, June 26, 2020EXTENSION 3 FILED
Friday, June 26, 2020TEAS EXTENSION RECEIVED
Saturday, January 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 9, 2020EXTENSION 2 GRANTED
Thursday, January 9, 2020EXTENSION 2 FILED
Thursday, January 9, 2020TEAS EXTENSION RECEIVED
Tuesday, June 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 7, 2019EXTENSION 1 GRANTED
Friday, June 7, 2019EXTENSION 1 FILED
Friday, June 7, 2019TEAS EXTENSION RECEIVED
Tuesday, January 15, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 3, 2018TTAB RELEASE CASE TO TRADEMARKS
Monday, December 3, 2018OPPOSITION TERMINATED NO. 999999
Monday, December 3, 2018OPPOSITION DISMISSED NO. 999999
Wednesday, August 30, 2017OPPOSITION INSTITUTED NO. 999999
Wednesday, May 31, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, May 2, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 2, 2017PUBLISHED FOR OPPOSITION
Wednesday, April 12, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 22, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 11, 2017ASSIGNED TO EXAMINER
Thursday, January 19, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, January 16, 2017NEW APPLICATION ENTERED IN TRAM